Estimated reading time at 200 wpm: 21 minutes

Clozapine, an atypical antipsychotic medication, is widely recognised as the most effective treatment for individuals with treatment-resistant schizophrenia (TRS).¹ Approved in 1989, its utilisation has grown, particularly for patients who have not responded adequately to other antipsychotic agents.³ Despite its superior therapeutic efficacy, clozapine carries a significant cautionary “black box warning” due to its association with rare but serious adverse effects, most notably agranulocytosis, but also considerable cardiovascular risks.⁵

It is important to note that, despite these risks, population-level studies have demonstrated that the overall all-cause mortality for individuals with serious psychotic illnesses prescribed clozapine is lower than for those receiving other treatments or no pharmacological intervention at all. This reduction is particularly pronounced for deaths by suicide and from natural causes.⁴ This complex risk-benefit profile underscores the critical imperative for clinicians to balance clozapine’s profound therapeutic advantages with the necessity of vigilant and proactive monitoring for its potentially life-threatening side effects.

Clozapine-Induced Myocarditis

Clozapine-induced myocarditis (CIM) is a severe and potentially fatal inflammatory condition affecting the heart muscle.⁷ Its recognition and management are paramount in clozapine therapy.

Incidence and typical onset

Reported incidence rates for CIM exhibit considerable variability across different studies and regions, ranging from as low as 0.06% to as high as 8.5% of treated patients.¹ A comprehensive meta-analysis indicated an event rate of 0.7% for myocarditis.¹ This wide range in reported incidence, coupled with varying mortality rates (from 12.5% to 33%) ³, suggests underlying challenges in the standardisation of diagnostic criteria and the consistency of reporting. For instance, higher rates have been reported in Australia.¹ Such discrepancies impede the accurate assessment of the true epidemiological burden of CIM and complicate direct comparisons across studies, highlighting a pressing need for universally adopted, clear diagnostic criteria and more rigorous reporting mechanisms to facilitate informed clinical decision-making.

The risk of CIM is demonstrably highest during the early phase of treatment, typically within the first two to eight weeks following initiation.¹ A significant proportion of cases manifest within one month of commencing clozapine.⁹ This consistent observation of early onset, combined with the often non-specific nature of initial symptoms, presents a substantial clinical challenge. Early signs such as tachycardia, fever, and flu-like illness ¹ can easily be misattributed to common, benign side effects of clozapine titration, or to intercurrent infections. This potential for misinterpretation can lead to critical delays in diagnosis, which in turn significantly increases the risk of morbidity and mortality.⁵ Consequently, intensive monitoring during this initial titration period is not merely advisable but essential to mitigate the serious risks associated with CIM. The mean age of patients at diagnosis has been reported as 33.5 years, with an average clozapine dose of 360 mg.³

Clinical presentation and diagnostic findings

The clinical presentation of CIM is often non-specific, making early identification particularly challenging.¹ Symptoms can closely mimic common clozapine side effects or a viral illness, including persistent tachycardia (especially at rest), fever, dyspnoea (shortness of breath), chest pain, malaise, and myalgia.

Key diagnostic indicators include elevated cardiac biomarkers. Troponin I or T, and creatine kinase MB (CKMB) are routinely measured. Troponin is generally considered a more useful marker of myocardial injury than CKMB, although its sensitivity can be variable, with one study reporting it as low as 35% in suspected cases.¹⁴ Inflammatory markers, such as C-reactive protein (CRP) and eosinophilia, are also frequently observed. Eosinophilia, when present, may appear several days after the troponin peak.¹⁵ Electrocardiogram (ECG) abnormalities, such as diffuse ST segment elevations, can also be indicative, though these are more classically associated with pericarditis. Echocardiography is a valuable tool for assessing ventricular function and confirming the development of ventricular failure, with global ventricular dysfunction being a predominant finding in many cases of CIM.³ In some instances, cardiac catheterisation may be performed to exclude obstructive or ischaemic coronary artery disease, thereby supporting a diagnosis of myocarditis.³ While the gold standard for diagnosing myocarditis remains histological examination of an endomyocardial biopsy, this is rarely a practical initial approach due to its invasive nature and the potential for patchy myocardial involvement, which can lead to false negatives.¹³

Prognosis and mortality

CIM is associated with significant morbidity and mortality if not detected and managed promptly.¹ Case fatality rates vary, with reports ranging from 12.5–24% ³ to 12.7% ¹, and in some literature as high as 33%.⁵ One published case series indicated fatalities in 10.3% of clozapine-treated patients who developed myocarditis.¹¹ Furthermore, compared to the general population, individuals treated with clozapine face a substantially elevated risk of myocarditis (17 to 322 times greater) and fatal myocarditis (14 to 161 times greater).¹¹ Fortunately, cardiac functional recovery typically occurs rapidly upon discontinuation of clozapine, with significant improvement often observed within five days, even in severe cases.³

Clozapine-Induced Cardiomyopathy

Clozapine-induced cardiomyopathy (CIC) is a distinct condition characterised by impaired heart muscle function, which can progress to heart failure.⁷ Its diagnosis is one of exclusion, requiring the absence of other known cardiac aetiologies such as coronary artery disease, hypertension, or valvular disease.¹⁸

Incidence and typical onset

The reported incidence of CIC also varies, with a meta-analysis indicating an event rate of 0.6%.¹ However, a study from Australia reported a considerably higher incidence of 4.65% in patients initiating clozapine, a figure significantly above those from national drug surveillance programmes.¹⁸ Other estimates for CIC incidence range from 0.02% in the United Kingdom to 0.1% in Australia ²⁰, and approximately 1 per 2000 patient-years.¹¹

CIC generally exhibits a more latent and insidious onset compared to myocarditis, typically presenting around nine months after clozapine initiation.⁹ However, the time to symptom development can range widely, from as early as three weeks to as late as four years, with an average onset time of 14.4 months.¹² This significantly later and more variable onset, coupled with the non-specific nature of its symptoms, necessitates long-term vigilance in monitoring patients on clozapine. The insidious progression of CIC means that monitoring protocols cannot be confined to the acute phase of treatment; a sustained, ongoing strategy for assessing cardiac function and general symptoms is essential over many months or even years after clozapine initiation. For example, one documented case took 40 months to diagnose ¹⁸, underscoring the potential for substantial diagnostic delays if clinicians are not alert to subtle, evolving changes in a patient’s overall health.

Clinical presentation and diagnostic findings

Patients with CIC may present with non-specific signs and symptoms characteristic of heart failure, including fatigue, dyspnoea, oedema, nausea, and vomiting.¹² It is noteworthy that typical peripheral oedema, a hallmark symptom in severe heart failure, may not always be prominent in CIC cases, which can further contribute to diagnostic delays.¹² Echocardiography is a critical diagnostic tool for assessing left ventricular (LV) function and detecting LV dilation.¹⁸ A reduced ejection fraction (EF) is a key diagnostic finding indicative of impaired cardiac pump function.¹² Chest X-rays (CXRs) demonstrating cardiomegaly (enlarged heart) can serve as a helpful early diagnostic indicator when heart failure is suspected. Furthermore, a normalisation of the cardio-mediastinal silhouette on CXR may be the first diagnostic imaging test to show improvement after clozapine discontinuation.¹² Cardiac magnetic resonance imaging (MRI) can also provide valuable detailed imaging for confirming cardiac dysfunction and inflammation.

Prognosis and mortality

Clozapine-induced cardiomyopathy can be fatal, with reported mortality rates ranging between 15% and 25%.⁶ A meta-analysis reported a case fatality rate of 7.8%.¹ Patients diagnosed with a left ventricular ejection fraction (LVEF) below 25% generally have a poorer prognosis, associated with higher mortality rates and more limited recovery of cardiac function.¹² Encouragingly, resolution of LV dilation and improvement in LVEF have been observed following the discontinuation of clozapine.¹⁸

Mechanisms of Clozapine-Induced Cardiotoxicity

The precise mechanisms by which clozapine induces cardiotoxicity, encompassing both myocarditis and cardiomyopathy, are not yet fully understood. However, several hypotheses have been proposed and are currently under investigation.

Leading hypothesis: IgE-mediated hypersensitivity reaction

The most widely accepted theory for clozapine-induced myocarditis posits an acute Type I (IgE-mediated) hypersensitivity reaction.⁵ This hypothesis is supported by observations of peripheral eosinophilia and, in some cases, eosinophilic infiltrates found in endomyocardial biopsy samples of affected patients.¹³ However, it is important to note that these findings are not consistently present in all cases, suggesting that other mechanisms may also be involved or that the hypersensitivity reaction itself can manifest with varying degrees of eosinophilic involvement.¹³

Other proposed mechanisms

Beyond the hypersensitivity reaction, several other mechanisms are considered plausible contributors to clozapine’s cardiotoxicity:

• Catecholaminergic activation: Elevated noradrenaline levels have been observed in patients treated with clozapine compared to those on other antipsychotics.¹³ While increased plasma noradrenaline can reflect existing left ventricular dysfunction, evidence suggests that catecholamines may directly cause cardiac dysfunction. For instance, increased plasma catecholamine levels have been implicated in takotsubo cardiomyopathy, a reversible form of LV dysfunction.¹³ This suggests that elevated catecholamine levels could contribute to the development of both myocarditis and cardiomyopathy in susceptible individuals.¹³
• Induction of free radicals and oxidative stress: Clozapine may induce the production of free radicals and oxidative stress within cardiac tissues, leading to cellular damage and inflammation.²¹
• Immune modulation and proinflammatory processes: Beyond the IgE-mediated response, clozapine may trigger broader immune modulation and proinflammatory processes, potentially including a cytokine release syndrome, contributing to myocardial inflammation.¹³
• Cytochrome P450 enzyme deficiencies: Deficiencies in cytochrome P450 1A2/1A3 enzymes have been suggested as a potential factor, which could alter clozapine metabolism and lead to accumulation of cardiotoxic metabolites.⁷
• Blockade of calcium-dependent ion channels: Another unproven mechanism involves the blockade of calcium-dependent ion channels, which could disrupt normal cardiac electrical activity and contractility.¹³
• Low serum selenium levels: Low serum selenium levels have also been proposed as a contributing factor, though this remains an unproven mechanism.¹³

It is also hypothesised that undiagnosed clozapine-related myocarditis may progress to cardiomyopathy, suggesting a continuum of cardiac injury.¹¹ The exact interplay of these mechanisms, and why some individuals develop cardiotoxicity while others do not, remains an active area of research.

Protocols for Early Detection of Clozapine-Associated Cardiac Pathologies

Given the potentially fatal nature of clozapine-associated cardiac pathologies, robust protocols for early detection are critical. These protocols typically involve a combination of baseline assessments, vigilant clinical monitoring, and serial biomarker testing, particularly during the high-risk initial weeks of treatment.

General principles for monitoring

A high index of suspicion is required due to the non-specific nature of symptoms.¹³ Prior to initiating clozapine, a comprehensive baseline assessment is crucial. This includes a thorough patient history, physical examination, and consideration of a pre-treatment ECG, especially in older patients or those with a family history of cardiac disease.⁷ Patients with pre-existing severe cardiac disease are generally contraindicated for clozapine.

Monash University protocol

The Monash University Protocol (download is here) developed based on an analysis of 75 cases of clozapine-related myocarditis, provides a structured approach for early detection.¹⁵ This protocol recommends:

• Baseline assessments: Prior to commencing clozapine, obtain baseline troponin I/T, C-reactive protein (CRP), and echocardiography.¹⁷
• Active monitoring (first 4 weeks): Monitor troponin and CRP on days 7, 14, 21, and 28 of treatment.¹⁷
• Response to abnormalities:
  • If there is a mild elevation in troponin or CRP, persistent abnormally high heart rate (≥120 bpm or a rise >30 bpm), or signs/symptoms consistent with an infective illness (e.g., fever, dyspnoea, flu-like symptoms), daily troponin and CRP investigations should be initiated until features resolve.¹⁵
  • Cessation of clozapine is advised if troponin is more than twice the upper limit of normal (ULN) or if CRP is over 100 mg/L.¹⁷
• Sensitivity: Combining these two parameters (troponin and CRP thresholds) has an estimated sensitivity of 100% for symptomatic clozapine-induced myocarditis.¹⁵ The sensitivity for asymptomatic disease, however, remains unknown.¹⁵ This protocol encourages continuation of clozapine in the presence of mild illness but defines clear thresholds for cessation.¹⁷

Other robust protocols

Several other guidelines, such as those from NHS Scotland and those aligned with NSW Health recommendations, provide similarly robust monitoring strategies.²⁴ These protocols generally include:

• Baseline measurements: A comprehensive set of baseline tests is required before clozapine initiation, including full blood count (FBC), urea/electrolytes, fasting glucose and lipids, liver function tests (LFTs), CRP, high sensitivity cardiac troponin, echocardiogram (Echo), electrocardiogram (ECG), weight, and waist circumference.²⁴ Pre-treatment white blood cell and neutrophil counts are also mandatory.⁷
• Early phase monitoring (first 4-8 weeks):
  • Weekly monitoring of Troponin I (or T) and high sensitivity CRP is recommended for the initial 4 to 8 weeks of treatment.⁷ Some guidelines extend this to six-monthly thereafter.²⁵
  • Vital signs (BP, pulse, temperature) and direct inquiry regarding symptoms should be assessed frequently, e.g., at least every alternate day for inpatients and weekly for outpatients.⁷
  • Clinical indicators of myocarditis to monitor for include fever (>38°C), chest pain, systolic blood pressure (SBP) <100 mmHg, heart rate >120 bpm, and shortness of breath.¹⁹
• Thresholds for intervention:
  • If high sensitivity cardiac troponin levels are only slightly raised (less than twice the upper limit of normal) and CRP remains less than 100 mg/L, clozapine may be continued, but daily troponin and CRP monitoring should be initiated.²⁴
  • Clozapine should be stopped, a cardiologist consulted, and an echocardiogram requested if CRP is >100 mg/L or troponin I is >2x ULN.⁷
  • An eosinophil count may also rise, but this is considered less consistent and often delayed.¹⁹
• Role of NT-proBNP: N-terminal B-type natriuretic peptide (NT-proBNP), released in response to ventricular wall stress, can be useful for detecting early and initially asymptomatic myocarditis, and is advised if such a condition is suspected.²⁵
• ECG and echocardiography: A baseline ECG is performed, with annual ECGs thereafter.⁷ Echocardiography is recommended at baseline and annually, or every 2 to 5 years if there is no serial change in LV function, and as clinically indicated.²⁵

Management implications of monitoring

If myocarditis or cardiomyopathy is suspected, clozapine treatment should be promptly discontinued.⁵ The patient should be immediately referred to a cardiologist for urgent diagnostic evaluation and supportive management.⁵

Supportive care may include administration of diuretics, beta-blockers, and angiotensin-converting enzyme inhibitors to support myocardial function during the acute insult.⁵ Trending inflammatory markers like ESR and CRP can help document recovery.⁵ For patients who have developed clozapine-induced myocarditis or cardiomyopathy, re-exposure to clozapine is generally not recommended due to the significant risk of recurrence and potential for severe outcomes.²⁰ The decision to rechallenge a patient with clozapine after myocarditis is controversial and requires careful consideration of the patient’s quality of life without clozapine versus the risks of rechallenge, often involving cardiology input and a very slow titration regimen.⁵ Successful rechallenge cases generally involve slower dose titration and more frequent monitoring than standard protocols.¹

Suggested Robust Protocol

Based on the comprehensive review of existing guidelines, a robust protocol for the early detection and investigation of clozapine-associated cardiac pathologies should integrate the most effective elements from various sources. This combined approach aims to maximise sensitivity for early detection while providing clear thresholds for intervention.

Pre-initiation assessment

Prior to commencing clozapine, a thorough baseline assessment is critical to identify pre-existing cardiac conditions and establish a reference point for monitoring.

• Comprehensive patient history and physical examination: Include a detailed cardiac history, family history of cardiac disease, and a physical examination to assess for any signs of cardiac dysfunction.
• Baseline laboratory tests:
  • Full blood count (FBC).²⁴
  • Urea/electrolytes.²⁴
  • Fasting glucose and lipids.²⁴
  • Liver function tests (LFTs).²⁴
  • C-reactive protein (CRP).¹⁷
  • High sensitivity cardiac troponin I or T (hs-cTnI/T).¹⁷
• Baseline cardiac imaging and electrophysiology:
  • Electrocardiogram (ECG): Essential for documenting baseline electrical activity and identifying any pre-existing abnormalities, especially in older patients or those with a family history of cardiac disease. Annual ECGs are recommended thereafter.⁷
  • Echocardiogram (Echo): Recommended at baseline to assess ventricular function and detect any pre-existing structural or functional abnormalities.¹⁷ Annual echocardiograms are recommended, or every 2 to 5 years if no serial change in LV function, and as clinically indicated.²⁵

Active monitoring during initial treatment phase (first 8 weeks)

This period is the highest risk for clozapine-induced myocarditis, necessitating intensive monitoring.

• Weekly biomarker monitoring:
  • Monitor high sensitivity cardiac troponin I (or T) and C-reactive protein (CRP) weekly for the initial 4 to 8 weeks of treatment.⁷ Some guidelines suggest extending this to six-monthly thereafter.²⁵
• Frequent clinical assessment:
  • Assess vital signs (blood pressure, pulse, temperature) and directly inquire about symptoms at least every alternate day for inpatients and weekly for outpatients.⁷
  • Monitor for clinical indicators of myocarditis, including:
    • Fever (>38°C).⁷
    • Chest pain.⁷
    • Systolic blood pressure (SBP) <100 mmHg.¹⁹
    • Heart rate (HR) >120 bpm or a rise >30 bpm.⁷
    • Shortness of breath (dyspnoea).⁷
    • Malaise, myalgia, or flu-like symptoms.¹¹

Response to abnormalities and intervention thresholds

Clear thresholds for intervention are crucial to prevent severe outcomes.

• Mild elevations/clinical suspicion:
  • If there is a mild elevation in troponin (≤2 times the upper limit of normal [ULN]) or CRP (50-100 mg/L), persistent abnormally high heart rate (≥120 bpm or a rise >30 bpm), or signs/symptoms consistent with an infective illness, daily troponin and CRP investigations should be initiated until features resolve.¹⁷ Clozapine may be continued with close daily monitoring in these cases.¹⁷
• Critical indicators for clozapine cessation:
  • Clozapine should be promptly stopped if:
    • CRP is >100 mg/L.¹⁷
    • Troponin I is >2 times the ULN.¹⁷
  • Immediate referral to a cardiologist for urgent diagnostic evaluation and supportive management is required.³
  • An echocardiogram should be requested immediately.²⁴
• Role of NT-proBNP: N-terminal B-type natriuretic peptide (NT-proBNP) can be useful for detecting early and initially asymptomatic myocarditis and is advised if such a condition is suspected.²⁵

Long-term monitoring for cardiomyopathy

Given the later and insidious onset of cardiomyopathy, ongoing vigilance is essential.

• Ongoing clinical assessment: Continue to assess for non-specific signs and symptoms of heart failure, such as fatigue, dyspnoea, oedema, nausea, and vomiting.¹²
• Periodic cardiac evaluations: Annual echocardiography is recommended, or every 2 to 5 years if there is no serial change in LV function, and as clinically indicated.²⁵
• Chest X-ray (CXR): Consider a baseline CXR in all patients starting clozapine. CXRs demonstrating cardiomegaly can be helpful when heart failure is suspected and may be the first diagnostic imaging test to normalise after clozapine discontinuation.¹⁸

Management implications

• Clozapine discontinuation: If myocarditis or cardiomyopathy is suspected or diagnosed, clozapine treatment should be promptly discontinued.³
• Cardiology referral: Immediate referral to a cardiologist for urgent diagnostic evaluation and supportive management is paramount.³
• Re-exposure: Re-exposure to clozapine after clozapine-induced myocarditis or cardiomyopathy is generally not recommended due to the significant risk of recurrence and potential for severe outcomes.⁶ Any decision to rechallenge should involve careful consideration of risks versus benefits, cardiology input, and a very slow titration regimen.³

Conclusions and Recommendations

Clozapine remains an indispensable medication for treatment-resistant schizophrenia, offering significant mortality benefits despite its known adverse effect profile. However, the associated cardiac pathologies, specifically myocarditis and cardiomyopathy, represent rare but potentially fatal complications that necessitate a high degree of clinical vigilance.

Clozapine-induced myocarditis typically manifests within the first few weeks of treatment, often with non-specific symptoms that can be easily overlooked or misattributed. The wide variation in reported incidence and mortality for myocarditis highlights a critical need for universally standardised diagnostic criteria and reporting mechanisms. Such standardisation would significantly improve the accuracy of epidemiological data, allowing for more precise risk assessment and ultimately enhancing patient safety.

Clozapine-induced cardiomyopathy, in contrast, tends to have a more latent and insidious onset, often developing many months or even years after treatment initiation. Its non-specific symptoms and prolonged diagnostic timeline underscore the necessity for sustained, long-term cardiac monitoring beyond the initial high-risk period.

The proposed mechanisms of cardiotoxicity, predominantly an IgE-mediated hypersensitivity reaction, along with catecholaminergic activation and other pathways, are still being fully elucidated. A deeper understanding of these mechanisms could pave the way for more targeted preventative strategies or novel interventions.

To mitigate the risks associated with these cardiac pathologies, robust protocols for early detection are paramount. Drawing upon the strengths of established guidelines, such as the Monash University protocol and other comprehensive recommendations, a multi-faceted monitoring approach is recommended:

1. Comprehensive baseline assessment: Prior to clozapine initiation, a thorough cardiac evaluation including patient history, physical examination, baseline ECG, echocardiography, and measurement of high sensitivity cardiac troponin and C-reactive protein is essential.
2. Intensive early phase monitoring: During the initial 4 to 8 weeks of treatment, which is the highest risk period for myocarditis, weekly monitoring of high sensitivity cardiac troponin and CRP is crucial. Daily monitoring of these biomarkers should be triggered by any clinical suspicion (e.g., persistent tachycardia, fever, dyspnoea, chest pain) or mild biomarker elevations.
3. Clear intervention thresholds: Clozapine cessation and immediate cardiology referral are warranted if CRP exceeds 100 mg/L or troponin levels are more than twice the upper limit of normal.
4. Long-term vigilance for cardiomyopathy: Given the delayed onset of cardiomyopathy, ongoing clinical assessment for symptoms of heart failure (fatigue, dyspnoea, oedema) and periodic cardiac evaluations (e.g., annual echocardiography) should continue throughout the patient’s treatment course. The utility of NT-proBNP for detecting asymptomatic cardiomyopathy should be considered.
5. Standardised reporting: The medical community should strive for consistent diagnostic criteria and reporting of clozapine-associated cardiac events to improve the understanding of their true incidence and facilitate evidence-based guidelines.

References

1. Systematic review and meta-analysis of rates of clozapine … https://www.researchgate.net/publication/338699709_Systematic_review_and_meta-analysis_of_rates_of_clozapine-associated_myocarditis_and_cardiomyopathy
2. Clozapine Management Clinical Guideline – Version 2 – SA Health https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/resources/policies/clozapine+management+clinical+guideline
3. Clozapine-induced Myocarditis Monitoring Guideline https://hnc.org.au/wp-content/uploads/2021/12/Draft-Clozapine-induced-Myocarditis-Monitoring-Guideline-2021.pdf
4. Clozapine Information Sheet https://www.nottsapc.nhs.uk/media/034fjrhy/clozapine-info-sheet.pdf
5. Clozapine-induced myocarditis | Oxford Medical Case Reports https://academic.oup.com/omcr/article/2018/1/omx080/4794785
6. Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition in https://mhc.kglmeridian.com/view/journals/mhcl/8/6/article-p303.xml
7. Suspected Clozapine-Induced Cardiomyopathy and Heart Failure With Reduced Ejection Fraction – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC6370400/
8. Zaponex Fact Sheet Myocarditis and cardiomyopathy – ZTAS Logon … https://www.ztas.com/PDF/FS_Myocarditis_cardiomyopathy_jan2021.pdf
9. Clozapine – Wikipedia https://en.wikipedia.org/wiki/Clozapine
10. Clozapine rechallenge following myocarditis: a systematic review of … https://www.cambridge.org/core/journals/cns-spectrums/article/clozapine-rechallenge-following-myocarditis-a-systematic-review-of-rechallenge-cases/C1B3EBA35B261BA8F245E005310D6CC9
11. Clozapine and Achy Breaky Hearts (Myocarditis and Cardiomyopathy) – Medsafe https://www.medsafe.govt.nz/profs/puarticles/clozapine.htm
12. CLOZAPINE-INDUCED MYOCARDITIS: A RARE CASE OF … – JACC https://www.jacc.org/doi/10.1016/S0735-1097%2823%2904225-0
13. Clozapine-induced cardiotoxicity: a clinical update – The Medical Journal of Australia https://www.mja.com.au/journal/2009/190/4/clozapine-induced-cardiotoxicity-clinical-update
14. New Monitoring Guidelines for Clozapine-Induced Myocarditis – Monash University https://www.monash.edu/__data/assets/pdf_file/0005/983453/poster_monitoringguidelines.pdf
15. Clozapine: safe prescribing – bpacnz https://bpac.org.nz/2017/clozapine.aspx
16. (PDF) Echocardiographic monitoring for clozapine cardiac toxicity: Lessons from real-world experience – ResearchGate https://www.researchgate.net/publication/235729187_Echocardiographic_monitoring_for_clozapine_cardiac_toxicity_Lessons_from_real-world_experience
17. Table 1 – Monitoring requirements for adult patients prescribed antipsychotics (except clozapine) https://www.cntw.nhs.uk/wp-content/uploads/2015/09/PPT-PGN-05-App1-MonReq-PtsPrescCloz-V02-Iss3-QTc-May17-1.pdf
18. Cardiac Complications of Clozapine Treatment – Assessment and Management – Psych Scene Hub https://psychscenehub.com/psychinsights/cardiac-complications-of-clozapine-treatment-assessment-and-management/
19. Guidelines for Prescribing and Monitoring Clozapine Purpose: To … https://www.smchealth.org/sites/main/files/file-attachments/guidelines_for_prescribing_and_monitoring_clozapine_8-10-24.pdf?1732576136
20. 00812-01 Clozapine and cardiovascular events v1.indd https://www.hcpinfo.clozaril.co.uk/-/media/clozarilcouk/pdf/download/00812_01_clozapine_and_cardiovascular_events_v1.pdf
21. (PDF) A New Monitoring Protocol for Clozapine-Induced Myocarditis Based on an Analysis of 75 Cases and 94 Controls – ResearchGate https://www.researchgate.net/publication/51080867_A_New_Monitoring_Protocol_for_Clozapine-Induced_Myocarditis_Based_on_an_Analysis_of_75_Cases_and_94_Controls
22. Suspected Clozapine-Induced Cardiomyopathy and Heart Failure With Reduced Ejection Fraction | MDedge – The Hospitalist https://community.the-hospitalist.org/content/suspected-clozapine-induced-cardiomyopathy-and-heart-failure-reduced-ejection-fraction
23. Association of CLOZARIL (clozapine) with cardiovascular toxicity – Novartis – Health https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2002/14697a-eng.php?_ga=1.157384250.1639504105.1414870219
24. www.monash.edu https://www.monash.edu/__data/assets/pdf_file/0008/983447/monitoringarticle_anzjp2011.pdf
25. Clozapine initiation and re-titration: Specialist Mental Health … https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/mental-health/clozapine-initiation-and-re-titration-specialist-mental-health-guidelines/